blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP4041237

EP4041237 - TARGETED TREATMENT OF CANCERS WITH DYSREGULATED FIBROBLAST GROWTH FACTOR RECEPTOR SIGNALING [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  15.07.2022
Database last updated on 02.09.2024
FormerThe international publication has been made
Status updated on  17.04.2021
Most recent event   Tooltip01.08.2024New entry: Decision on request for further processing 
Applicant(s)For all designated states
G1 Therapeutics, Inc.
700 Park Offices Drive, Suite 200
Research Triangle Park, NC 27709 / US
[2022/33]
Inventor(s)01 / STRUM, Jay Copeland
616 Deerhaven Court
Hillsborough, NC 27278 / US
02 / WHITWORTH, Chloe
c/o G1 Therapeutics, Inc. 700 Park Offices Drive
Suite 200
Research Triangle Park, NC 27709 / US
03 / FREED, Daniel M.
c/o G1 Therapeutics, Inc. 700 Park Offices Drive
Suite 200
Research Triangle Park, NC 27709 / US
 [2022/33]
Representative(s)Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
[2022/33]
Application number, filing date20874071.209.10.2020
[2022/33]
WO2020US55146
Priority number, dateUS201962913055P09.10.2019         Original published format: US 201962913055 P
[2022/33]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2021072319
Date:15.04.2021
Language:EN
[2021/15]
Type: A1 Application with search report 
No.:EP4041237
Date:17.08.2022
Language:EN
The application published by WIPO in one of the EPO official languages on 15.04.2021 takes the place of the publication of the European patent application.
[2022/33]
Search report(s)International search report - published on:US15.04.2021
(Supplementary) European search report - dispatched on:EP27.09.2023
ClassificationIPC:A61K31/498, A61K31/519, A61K31/506, A61P35/00, A61K45/06
[2023/43]
CPC:
A61K45/06 (EP,CN,KR,US); A61K31/519 (EP,CN,KR,US); A61K31/498 (EP,CN,KR,US);
A61P35/00 (EP,CN,KR,US); A61K2300/00 (KR)
C-Set:
A61K31/498, A61K2300/00 (CN,EP);
A61K31/519, A61K2300/00 (CN,EP)
Former IPC [2022/33]A61K31/506, A61K31/519, A61P35/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2022/33]
TitleGerman:GEZIELTE BEHANDLUNG VON KREBS MIT DYSREGULIERTER FIBROBLASTENWACHSTUMSFAKTORREZEPTORSIGNALISIERUNG[2022/33]
English:TARGETED TREATMENT OF CANCERS WITH DYSREGULATED FIBROBLAST GROWTH FACTOR RECEPTOR SIGNALING[2022/33]
French:TRAITEMENT CIBLÉ DE CANCERS AVEC UNE SIGNALISATION DE RÉCEPTEUR DE FACTEUR DE CROISSANCE DES FIBROBLASTES DÉRÉGULÉE[2022/33]
Entry into regional phase09.05.2022National basic fee paid 
09.05.2022Search fee paid 
09.05.2022Designation fee(s) paid 
09.05.2022Examination fee paid 
Examination procedure09.05.2022Examination requested  [2022/33]
23.05.2024Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
23.07.2024Amendment by applicant (claims and/or description)
23.07.2024Date on which the examining division has become responsible
Request for further processing for:The application is deemed to be withdrawn due to failure to indicate the wish to proceed further with the application
23.07.2024Request for further processing filed
23.07.2024Full payment received (date of receipt of payment)
Request granted
31.07.2024Decision despatched
The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report
23.07.2024Request for further processing filed
23.07.2024Full payment received (date of receipt of payment)
Request granted
31.07.2024Decision despatched
Fees paidRenewal fee
09.05.2022Renewal fee patent year 03
24.08.2023Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[Y]CA3054455  (BETTA PHARMACEUTICALS CO LTD [CN]) [Y] 1-17* p. 121, table 9 *;
 [Y]WO2019136451  (G1 THERAPEUTICS INC [US]) [Y] 1-17 * p. 3, l. 29 to p. 4, l. 3; p. 5, l. 2-5; p. 7, l. 3-12, p. 37, l. 12; p. 38, l. 7; p. 41, l. 27; p. 93, l. 16-25 *;
 [Y]  - Sorrentino Jessica, "The CDK4/6 inhibitor G1T38 enhances response to targeted therapies in preclinical models of non-small cell lung cancer", (20180701), URL: https://aacrjournals.org/cancerres/article/78/13_Supplement/1522/625777/Abstract-1522-The-CDK4-6-inhibitor-G1T38-enhances, (20210927), XP055845057 [Y] 1-17 * the whole document *
 [Y]  - MAHIPAL AMIT ET AL, "FGFR2 genomic aberrations: Achilles heel in the management of advanced cholangiocarcinoma", CANCER TREATMENT REVIEWS, ELSEVIER, AMSTERDAM, NL, vol. 78, doi:10.1016/J.CTRV.2019.06.003, ISSN 0305-7372, (20190622), pages 1 - 7, (20190622), XP085782604 [Y] 1-17 * p. 1, left col. last sentence; chapter FGFR aberrations in cholangiocarcinoma; chapter Selective small molecule TKIs; Table 3 *

DOI:   http://dx.doi.org/10.1016/j.ctrv.2019.06.003
International search[A]US2012237511  (LONG LI [US], et al) [A] 1-6, 34-36, 62-64, 75-78,115, 117-120, 123/(115,117-120), 135, 137-140,143/(135, 137-140), 155-160, 163/(155-160) * ; entire document *;
 [A]US2012251538  (HARDING THOMAS [US], et al) [A] 1-6, 34-36, 62-64, 75-78,115, 117-120, 123/(115,117-120), 135, 137-140,143/(135, 137-140), 155-160, 163/(155-160)* ; entire document *;
 [YA]WO2019006393  (G1 THERAPEUTICS INC [US]) [Y] 120, 123/120, 140, 143/140, 160, 163/160 * ; pg. 2, In 1-5, pg. 69, In 13-14, pg. 71, In 28 * [A] 1-6, 34-36, 62-64, 75-78, 115, 117-119, 123/(115, 117-119), 135, 137-139, 143/(135, 137-139), 155- 159, 163/(155-159);
 [A]US2019175598  (SELVARAJ ANAND [US], et al) [A] 1-6, 34-36, 62-64, 75-78,115, 117-120, 123/(115,117-120), 135, 137-140,143/(135, 137-140), 155-160, 163/(155-160) * ; abstract, para [0004], [0012], [0023] *;
 [YA]  - Loriot Yohann, Necchi Andrea, Park Se Hoon, Garcia-Donas Jesus, Huddart Robert, Burgess Earle, Fleming Mark, Rezazadeh Arash, Mellado Begoña, Varlamov Sergey, Joshi Monika, Duran Ignacio, Tagawa Scott T., Zakharia Yousef, Zhong Bob, Stuyckens Kim, Santiago-Walker Ademi, De Porre Peter, O’hagan Anne, Avadhani Anjali, Siefker-Radtke Arlene O., "Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma", The New England journal of medicine, US , (20190725), vol. 381, no. 4, doi:10.1056/NEJMoa1817323, ISSN 0028-4793, pages 338 - 348, XP055920378 [Y] 120, 123/120, 140,143/140, 160, 163/160 * ; pg. 338, para 1, pg. 339, right col, para 3 * [A] 1-6, 34-36, 62-64, 75-78,115, 117-119, 123/(115,117-119), 135, 137-139,143/(135, 137-139), 155-159, 163/(155-159)

DOI:   http://dx.doi.org/10.1056/NEJMoa1817323
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.